BTIG Research Reaffirms Buy Rating for Mobia Medical (NASDAQ:MOBI)

Key Points

• BTIG Research reaffirmed its Buy rating on Mobia Medical with a $19 price target, implying approximately 51% upside from the current price. Analysts overall maintain a “Moderate Buy” consensus with a $20.25 average target.
• Mobia Medical’s second-quarter revenue more than doubled year over year to $13.51 million, while management forecast 2026 revenue of $54 million to $56 million and raised approximately $134 million in IPO proceeds to fund growth.
• The company remains unprofitable: quarterly loss per share of $1.10 missed the expected $0.83 loss, and analysts project a full-year loss of about $2.50 per share.

Mobia Medical (NASDAQ:MOBI - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at BTIG Research in a research report issued on Wednesday,Benzinga reports. They currently have a $19.00 price target on the stock. BTIG Research's price objective would suggest a potential upside of 51.03% from the stock's current price.

A number of other research firms have also recently weighed in on MOBI. Wall Street Zen raised Mobia Medical from a "sell" rating to a "hold" rating in a report on Sunday, June 14th. Wolfe Research started coverage on Mobia Medical in a research note on Tuesday, June 2nd. They issued an "outperform" rating for the company. Bank of America initiated coverage on Mobia Medical in a report on Tuesday, June 2nd. They set a "buy" rating and a $16.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They set an "overweight" rating and a $15.00 price objective on the stock. Finally, The Goldman Sachs Group started coverage on shares of Mobia Medical in a report on Tuesday, June 2nd. They issued a "buy" rating and a $31.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $20.25.

Mobia Medical Price Performance

MOBI stock opened at $12.58 on Wednesday. Mobia Medical has a 1 year low of $10.19 and a 1 year high of $15.29. The company has a market capitalization of $418.27 million and a PE ratio of -0.65. The company has a fifty day moving average of $12.54.

Mobia Medical (NASDAQ:MOBI - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.27). The firm had revenue of $13.51 million for the quarter. The company's quarterly revenue was up 102.4% on a year-over-year basis. Analysts predict that Mobia Medical will post -2.5 EPS for the current fiscal year.

Insider Activity at Mobia Medical

In other news, CFO Nelson Bunker Curnes bought 5,000 shares of the company's stock in a transaction that occurred on Tuesday, June 9th. The shares were purchased at an average price of $12.79 per share, with a total value of $63,950.00. Following the completion of the acquisition, the chief financial officer directly owned 366,997 shares in the company, valued at approximately $4,693,891.63. This trade represents a 1.38% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Mobia Medical News Roundup

Here are the key news stories impacting Mobia Medical this week:

• Positive Sentiment: Second-quarter revenue reached $13.5 million, up 102% year over year, while gross margin was a strong 83.2%. Management also reported durable two-year clinical benefits from its VNS-REHAB stroke-recovery therapy, including improvements in motor function, daily living activities and quality of life. Mobia Medical Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Mobia Medical raised approximately $134 million in net proceeds through its initial public offering, providing additional capital to support commercialization, research and corporate operations. Mobia Medical Q2 2026 Earnings Call Highlights
• Positive Sentiment: The company forecast 2026 revenue of $54 million to $56 million, representing approximately 69% to 75% growth and exceeding the roughly $53.5 million analyst consensus. Mobia Medical Forecasts 2026 Revenue
• Neutral Sentiment: Reported short-interest data showed zero shares sold short and a zero-day short-interest ratio, but the accompanying percentage change was listed as “NaN,” making the data unreliable and unlikely to provide a meaningful trading signal.
• Negative Sentiment: Mobia Medical reported a $1.10 per-share loss, wider than the expected $0.83 loss. The company remains unprofitable, and analysts expect a full-year loss of approximately $2.50 per share, which may keep pressure on the stock despite rapid top-line growth. Mobia Medical Quarterly Earnings Report

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source